COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - Share repurchase programme

13/06/2017 - 13:21

Bagsværd, Denmark, 13 June 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]

Midatech Pharma Plc: R&D manufacturing site visit for investors and analysts

13/06/2017 - 13:00

13 June 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") R&D manufacturing site visit for investors and analysts Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical [...]

Summit Therapeutics plc : Notice of Results

13/06/2017 - 13:00

Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 ON 14 JUNE 2017 Oxford, UK, 13 June 2017 - Summit Therapeutics plc (AIM: SUMM [...]

Acarix Receives First Commercial Order For CADScor®System For Early Detection Of Coronary Artery Disease From Danish Hospital

13/06/2017 - 11:00

Press release Malmö, June 13, 2017 Acarix Receives First Commercial Order For CADScor ® System For Early Detection Of Coronary Artery Disease From Danish Hospital Commercialization program on track Acarix AB (publ) (" [...]

Silmäasema Oyj: Managers' Transactions - Kaisa Vikkula

13/06/2017 - 10:00

Silmäasema Oyj - Managers' Transactions Kaisa Vikkula 13 June 2017, at 11.00 a.m. ____________________________________________ Person subject to the notification requirement Name: Vikkula, Kaisa Position: Member of the [...]

Silmäasema Oyj: Managers' Transactions - Anu Kankkunen

13/06/2017 - 10:00

Silmäasema Oyj - Managers' Transactions Anu Kankkunen 13 June 2017, at 11 a.m. ____________________________________________ Person subject to the notification requirement Name: Kankkunen, Anu Marjut Position: CFO Issuer [...]

Silmäasema Oyj: Managers' Transactions - Torsti Sihvola

13/06/2017 - 10:00

Silmäasema Oyj - Managers' Transactions Torsti Sihvola 13 June 2017, at 11.00 a.m. ____________________________________________ Person subject to the notification requirement Name: Sihvola, Torsti Position: Member of [...]

FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants

13/06/2017 - 09:00

FIT Biotech Oy Company release June 13, 2017 at 10:00 am FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants On September 26, 2016, the Board of Directors of FIT Biotech Oy ( [...]

Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole

13/06/2017 - 07:15

Basel, Switzerland, June 13, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has been awarded USD 54.8 million for two additional options on its existing contract with the Biomedical Advanced [...]

Biocartis Group NV: Disclosure of a transparency notification

13/06/2017 - 07:01

PRESS RELEASE: REGULATED INFORMATION 13 June 2017, 07:01 CEST Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Mechelen, Belgium, [...]

ABLYNX APPOINTS MARKUS EWERT AS CHIEF BUSINESS OFFICER

13/06/2017 - 07:00

GHENT, Belgium, 13 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced the appointment of Markus L.E. Ewert, PhD, MBA, as Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will [...]

argenx to Present at JMP Securities Life Sciences Conference

13/06/2017 - 07:00

June 13, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Biocartis Group NV: Biocartis launches CE-marked IVD test for lung cancer

13/06/2017 - 07:00

PRESS RELEASE: 13 June 2017, 07:00 CEST Biocartis launches CE-marked IVD test for lung cancer Idylla(TM) EGFR Mutation Test is the only on market fully automated CE-IVD test detecting all relevant EGFR mutations [...]

TiGenix Launches Global Phase III Trial for Cx601

13/06/2017 - 07:00

PRESS RELEASE TiGenix Launches Global Phase III Trial for Cx601 Leuven (BELGIUM) - June 13, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting [...]

Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial

12/06/2017 - 23:15

San Diego, US, 12 June 2017 - Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba ® (insulin [...]

ProLynx présente PLX039, un système d'administration de médicament sous forme de microsphères d'hydrogel impliquant la prise mensuelle unique d'un agoniste de récepteur GLP 1

12/06/2017 - 21:12

SAN FRANCISCO, le 12 juin 2017 (GLOBE NEWSWIRE) - Dans un abrégé de dernière minute, lors du 77 e congrès de l'American Diabetes Association à San Diego, ProLynx LLC a présenté un nouveau système d'administration de [...]

Silmäasema Oyj: Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act

12/06/2017 - 20:15

Silmäasema Oyj: Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act Stock Exchange Release 12 June 2017, at 9.15 p.m. Silmäasema Oyj (the "Company") has today [...]

XBiotech annonce l'interruption de l'étude de phase III pour le cancer colorectal sur la base de la deuxième analyse intermédiaire

12/06/2017 - 19:43

AUSTIN, Texas, le 9 juin 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ:XBIT) a annoncé aujourd'hui qu'un Comité indépendant de surveillance et de suivi des données (IDMC) a réalisé une analyse prospective sans insu de l [...]

Ossur Hf : Transactions in relation to share buyback program

12/06/2017 - 18:00

Announcement from Össur hf. No. 44/2017 Reykjavík, 12 June 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]